May 09, 2012

Macitentan in Combo With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Share this content:

Macitentan in Combo With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Sponsors and Collaborators

Actelion

Contact

Charles Conrad, MD

MD Anderson Cancer Center

713-792-2883

ClinicalTrials.gov Identifier

NCT01499251

Recommended for you

Related Resources

News

Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

You must be a registered member of Cancer Therapy Advisor to post a comment.

Click here to login | Click here to register

Sign Up for Free e-newsletters

I would like to receive relevant information via email from Cancer Therapy Advisor / Haymarket Medical Network.

By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer	Regimens	Drugs
Brain Cancer	Regimens	Drugs
Breast Cancer	Regimens	Drugs
Endocrine Cancer	Regimens	Drugs
Gastrointestinal Cancer	Regimens	Drugs
Gynecologic Cancer	Regimens	Drugs
Head and Neck Cancer	Regimens	Drugs
Hematologic Cancer	Regimens	Drugs
Lung Cancer	Regimens	Drugs
Other Cancers	Regimens
Prostate Cancer	Regimens	Drugs
Rare Cancers	Regimens
Renal Cell Carcinoma	Regimens	Drugs
Skin Cancer	Regimens	Drugs
Urologic Cancers	Regimens	Drugs

More

Macitentan in Combo With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Related Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings

Cancer Therapy Advisor Articles